BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
|
|
| Completed | 3 | 463 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo, Topical corticosteroid | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 11/19 | 04/23 | | |
NCT05149313 / 2021-002967-23: A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine |
|
|
| Completed | 3 | 331 | Europe | Lebrikizumab, Lebrikizumab-matching Placebo | Almirall, S.A. | Dermatitis, Atopic, Eczema | 01/23 | 05/24 | | |
NCT04743739: Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN |
|
|
| Recruiting | 3 | 126 | RoW | Rituximab, CD20 antibody, cyclosporine, CsA | Peking Union Medical College Hospital, Beijing Tongren Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, The Luhe Teaching Hospital of the Capital Medical University, The Seventh Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Xinjiang Medical University, Nanyang Nanshi Hospital of Henan University, Shanghai Fosun Pharmaceutical Development Co, Ltd. | Idiopathic Membranous Nephropathy | 03/23 | 03/25 | | |
NCT05862233: A Clinical Study of MIL62 in Primary Membranous Nephropathy |
|
|
| Recruiting | 3 | 150 | RoW | MIL62, Cyclosporine | Beijing Mabworks Biotech Co., Ltd. | Primary Membranous Nephropathy | 12/24 | 06/26 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Not yet recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
